Skip to main content
MAZE logo

MAZE · Maze Therapeutics, Inc.

Track MAZE — free
$31.37 -1.06 (-3.27%) At close · Nov 20
Market Cap
$1.72B
Shares
54.68M
Volume · Nov 20 818.95K Avg daily vol (3M) 730.21K

Price & Indicators

 

Key stats

Close
$31.37
Fri 20 Nov
Open
$31.77
Fri 20 Nov
Average volume, 30 days
745K
shares a session
Short interest
6.7M
12.2% of shares · 8.8 days to cover
Day range
$30.88$32.80
Open $31.77 Close $31.37
52-week closing range
$22.39$51.84
Close $31.37 39.5% under the high
Short volume, last session
65%
Last earnings
Mar 25, 2026
Latest filing
10-Q · Nov 9
Price history
Jan 2025 to Nov 2026

Latest documents

2026
Nov 17
Investor event
Horizon Phase II study completes enrollment; data due early 2027

Maze Therapeutics has completed enrollment in its Phase II Horizon study, with more than 50 patients enrolled. An administrative analysis showed clear UACR reduction across a broad spectrum of patients and a response rate over 50%. The company said it has data in early 2027 and that its capital funds those catalysts into 2029.

6 source passages
We've completed enrollment in what we call our Phase II study, which is the Horizon Study. We have more than 50 patients that we've been able to enroll into the study. We've completed enrollment with data in early 2027. So what we demonstrate is clear UACR reduction across a broad spectrum of patients. We did have a response rate over 50%, which was one of our goals. we do have the capital to fund all of these particular data catalysts that we've been describing, as well as be funded into 2029. Open the document at this passage
Nov 10
Investor event
Renal study exceeds enrollment target as PKU advances

Maze Therapeutics said its renal study enrolled over 50 patients, exceeding the prior target of 30 to 45. MZE782 began on schedule, with PKU data expected in 27, while a chronic kidney disease study is planned to start in 2027.

6 source passages
Jason Coloma, the CEO of Maze Therapeutics, as our next presenting company. We had talked about and guided previously that we would have, across three different cohorts, 10 to 15 patients. So that's 30 to 45. We've actually exceeded that, over 50 patients enrolled into the study. We have a second program, SOC6A19 inhibitor, called MZE782. Earlier in the year, we had guided that we would be able to start that study by the middle of the year. We did that on time, as we had promised our investors. We're excited about being able to enroll that study and being able to have that data in 27. We also highlighted a few things that we've been able to do operationally, and then our balance sheet Strong that gets us through all of the different data catalysts that we will be upcoming What we described in our earnings was the ability to start that study in 2027. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
MZE829 Phase 2 data positive as losses widen

Maze Therapeutics reported positive MZE829 Phase 2 data in 15 patients, showing a clinically meaningful mean reduction in proteinuria without serious adverse events. Nine-month net loss was $116.9 million; cash and marketable securities totaled $477.0 million as of September 30, 2026.

Net loss $47.97M Diluted EPS -$0.79
Read from the MD&A section
5 source passages
In March 2026, we announced positive topline clinical proof of concept data from our Phase 2 trial of MZE829 in patients with AMKD, in which we enrolled 15 patients. The results demonstrated that treatment with MZE829 led to a clinically meaningful mean reduction in proteinuria, as measured by urinary albumin-to-creatinine ratio. MZE829 was generally well tolerated, with no serious adverse events or severe treatment-related adverse events reported. During the three and nine months ended September 30, 2026, we incurred a net loss of $48.0 million and $116.9 million, respectively. As of September 30, 2026, we had cash, cash equivalents and marketable securities of $477.0 million. Open the document at this passage
Nov 9
Current report 8-K
HORIZON enrollment complete; final data expected early 2027

Maze Therapeutics completed HORIZON enrollment in more than 50 patients across three cohorts, expects final MZE829 data in early 2027, and reported $477.0 million in cash, cash equivalents and marketable securities as of September 30, 2026.

Financial results
3 source passages
Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027 Enrollment for the Phase 2 HORIZON trial evaluating MZE829 in more than 50 patients in a broad AMKD population is complete and exceeded the target enrollment range of 10-15 patients per cohort as previously guided. Cash, cash equivalents and marketable securities were $477.0 million as of September 30, 2026, compared to $360.0 million as of December 31, 2025. Open the document at this passage
Oct 16
Current report 8-K Events of Oct 15
Entered into a material agreement, Unregistered sale of equity

Maze Therapeutics exchanged 2,776,007 shares of its common stock held by Frazier Life Sciences affiliates for pre-funded warrants to purchase an equivalent number of shares at $0.001 per share, leaving 53,931,889 shares outstanding as of October 16, 2026.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$151.47M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
34.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-6.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$350.54M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+33.0%
Year over year · more shares
Price change (1Y)
-11.8%
Trailing year
Short interest
12.2%
Latest settlement · 8.8 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +1%
above
Price vs 50-day avg +7%
above
RSI (14) 47
neutral
MACD trend Negative
52-week position 30%
mid-range
Momentum
relative strength
Strong
1-month return +1%
trailing
6-month return +29%
trailing
YTD return −24%
this year
Relative strength +38%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $29 › 200d $31 — 200d above 50d
Institutional flow Distributing
-1% holders QoQ · +21 funds added
Insider flow Distributing
Net -$1.1M over 90 days · 100% sells
Short interest Falling
12.22% of shares out · ▼ -11.2% MoM · 8.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
161 holders — mid 2-yr range
Squeeze score 79
high risk · 0–100
Fundamentals
Weak
EPS growth −344%
Y/Y
Free cash flow $-112.7M
Balance sheet $189.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 67%
annualized · 1-yr
Max drawdown −57%
past year
ATR 6.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+1% Bullish
Price vs 50-day avg
+7% Bullish
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
30% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $29 › 200d $31 — 200d above 50d
Institutional flow Distributing
-1% holders QoQ · +21 funds added
Insider flow Distributing
Net -$1.1M over 90 days · 100% sells
Short interest Falling
12.22% of shares out · ▼ -11.2% MoM · 8.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
161 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $22 Now $31 · 30% Range high $52
vs 200-day avg +1% vs 50-day avg +7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Discovery research and other programs 3.45M three months ended September 30, 2026 filing —
MZE782 5.55M three months ended September 30, 2026 filing —
MZE829 7.06M three months ended September 30, 2026 filing —
net proceeds $14.4M three months ended September 30, 2026 filing —
shares of its common stock 548,723 three months ended September 30, 2026 filing —
weighted average price $27.42 three months ended September 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MAZE
Maze Therapeutics, Inc.
this stock
$1.72B -24.3% — — 12.2%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
161
% held
110.4%
Net QoQ
+1.8M sh
Top holder
Frazier Life Sciences Man…
Held Float
View
Held by Funds
Fund positions
174
View
Short & Settlement
Short Interest Falling
Shares short
6.7M
Days to cover
8.8d
Change
-843.3K sh
View
Short Volume
Short vol %
65%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
27.0K
Value
$862.1K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
48.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$1.1M
Buyers / Sellers
0 / 4
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$167.5M
Net income (FY)
$-131.1M
EPS diluted
$-3.05
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
23

Maze Therapeutics has completed enrollment in its Phase II Horizon study, with more than 50 patients enrolled. An administrative analysis showed clear UACR reduction across a broad spectrum of patients and a response rate over 50%. The company said it has data in early 2027 and that its capital funds those catalysts into 2029.

View
Proposed Sales
Value
$1.1M
Shares
34.5K
Filed
Nov 2, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Maze Therapeutics Reports Third Q…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
MAZE -8.6% +1.2% +29.2% -0.4% -24.3%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -0.1% +10.4% +38.3% +8.4% -25.4%
Key facts CIK 1842295 CUSIP 578784100 13F (30d) 158 filings 153 filers Visit website Investor relations